Compendium of Cancer Genome Aberrations

GTS5:Volunteer Assignments and Opportunities: Difference between revisions

(View all pending changes)
[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 20: Line 20:
|-
|-
|
|
==== CHAPTER 2 (GROWTH FACTOR RECEPTORS AND RELATED SIGNALLING PATHWAYS) ====
====CHAPTER 2 (GROWTH FACTOR RECEPTORS AND RELATED SIGNALLING PATHWAYS)====
|
|
----<br />
----<br />
Line 138: Line 138:
|
|
|Named based on GTS5 book. Also, content in online WHO EYE5, EYE5, HAN5, ENDO5, PEDS5, CNS5, SBTB5, BRST5.
|Named based on GTS5 book. Also, content in online WHO EYE5, EYE5, HAN5, ENDO5, PEDS5, CNS5, SBTB5, BRST5.
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[GTS5:NF2-related_schwannomatosis_(NF2)|NF2-related schwannomatosis (NF2)]]
|[[GTS5:NF2-related_schwannomatosis_(NF2)|NF2-related schwannomatosis (NF2)]]
Line 251: Line 262:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[GTS5:WT1_related_tumour_predisposition_syndrome_(WT1)|WT1 related tumour predisposition syndrome (WT1)]]
|[[GTS5:WT1_related_tumour_predisposition_syndrome_(WT1)|WT1 related tumour predisposition syndrome (WT1)]]
Line 361: Line 383:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[GTS5:Brooke-Spiegler_syndrome_(CYLD)|Brooke-Spiegler syndrome (CYLD)]]
|[[GTS5:Brooke-Spiegler_syndrome_(CYLD)|Brooke-Spiegler syndrome (CYLD)]]
Line 460: Line 493:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|
|
==== CHAPTER 3 (OXIDATIVE STRESS RESPONSE AND METABOLISM) ====
====CHAPTER 3 (OXIDATIVE STRESS RESPONSE AND METABOLISM)====
|
|
----<br />
----<br />
Line 527: Line 571:
|-
|-
|
|
==== CHAPTER 4 (CELL CYCLE AND APOPTOSIS PATHWAYS) ====
====CHAPTER 4 (CELL CYCLE AND APOPTOSIS PATHWAYS)====
|
|
----<br />
----<br />
Line 590: Line 634:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[GTS5:CDK4-related_melanoma_predisposition_syndrome_(CDK4)|CDK4-related melanoma predisposition syndrome (CDK4)]]
|[[GTS5:CDK4-related_melanoma_predisposition_syndrome_(CDK4)|CDK4-related melanoma predisposition syndrome (CDK4)]]
Line 614: Line 669:
|-
|-
|
|
==== CHAPTER 5 (DNA REPAIR AND GENOMIC STABILITY) ====
====CHAPTER 5 (DNA REPAIR AND GENOMIC STABILITY)====
|
|
----<br />
----<br />
Line 716: Line 771:
|
|
|Named based on GTS5 book (page created on 6/11/24). Also, content in online WHO HAEM5, HAN5, CNS5.
|Named based on GTS5 book (page created on 6/11/24). Also, content in online WHO HAEM5, HAN5, CNS5.
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[GTS5:MUTYH-associated_polyposis_(MUTYH)|MUTYH-associated polyposis (MUTYH)]]
|[[GTS5:MUTYH-associated_polyposis_(MUTYH)|MUTYH-associated polyposis (MUTYH)]]
Line 826: Line 892:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[GTS5:Rothmund-Thomson_syndrome_(ANAPC1,_RECQL4)|Rothmund-Thomson syndrome (ANAPC1, RECQL4)]]
|[[GTS5:Rothmund-Thomson_syndrome_(ANAPC1,_RECQL4)|Rothmund-Thomson syndrome (ANAPC1, RECQL4)]]
Line 897: Line 974:
|-
|-
|
|
==== CHAPTER 6 (TELOMERE MAINTENANCE) ====
====CHAPTER 6 (TELOMERE MAINTENANCE)====
|
|
----<br />
----<br />
Line 938: Line 1,015:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|
|
==== CHAPTER 7 (EPIGENETIC DRIVERS AND CHROMATIN REMODELLING) ====
====CHAPTER 7 (EPIGENETIC DRIVERS AND CHROMATIN REMODELLING)====
|
|
----<br />
----<br />
Line 1,027: Line 1,115:
|-
|-
|
|
==== CHAPTER 8 (RNA REGULATION) ====
====CHAPTER 8 (RNA REGULATION)====
|
|
----<br />
----<br />
Line 1,079: Line 1,167:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|
|
==== CHAPTER 9 (PROTEIN REGULATION) ====
====CHAPTER 9 (PROTEIN REGULATION)====
|
|
----<br />
----<br />
Retrieved from "https://test.ccga.io/index.php/GTS5:Volunteer_Assignments_and_Opportunities"